fda warning letters glp-1 september 2025 takes aim at telehealth companies for promoting unofficial weight loss drug dupes FDA ramps up its pushback

Jelinkova, P., Splichal, Z., Jimenez, A., Haddad, Y., Mazumdar, A., Sur, V.P., et al., Infect

Until the data of the SURPASS-CVOT trial are available, tirzepatide will most likely have a place in the algorithm of T2D therapy for patients with obesity and T2D that have the therapeutic aim to normalize glycemia and decrease body weight

PMC: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing PMC: Regeneration or Risk

NF1 is characterized by multiple benign neurofibromas, caf-au-lait spots, and an increased lifetime risk (approximately 813%) of developing MPNST (Evans et al., 2021)

Reprod Biomed Online (2002) 5:11724

The advisory calls for customising treatment protocols for individual patients: -Identify early warning signs of muscle loss -Optimize protein intake and exercise prescriptions -Track true therapeutic success beyond the scale Is your practice ready